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Coronary artery diseaseBackground: The angiostatic factor endostatin (ES) plays an important role as mediator of angiogenesis. Elevated
osteopontin (OPN) was associated with valve calciﬁcation in healthy individuals. The present study aimed to in-
vestigate ES and OPN levels in patients with both coronary artery disease (CAD) and aortic valve calciﬁcation
(AVC).
Methods and results: In total 224 non- or ex-smoking patients (161 male, mean age: 61.09 ± 11.02 years; 63 fe-
male:mean age: 67.49±7.87 years)with angiographically veriﬁed andquantiﬁedCADwere recruited. SerumES
and plasma OPN levels were measured by ELISA and AVC was evaluated by a parasternal short axis view and
quantiﬁed as non-, mild or moderate/severe. There was a stepwise increase of ES measurable with increasing
severity of AVC, independent from age, BMI and CAD-severity (p= 0.018; F = 4.09). OPN also increased signif-
icantlywith the grade of AVC severity (p= 0.029; F= 3.61) but was no longer signiﬁcant when the co-variables
(p = 0.31; F = 1.18) were inserted.
Conclusions: This is the ﬁrst study showing an association of ES with AVC in CAD-patients independent from age,
BMI and CAD-severitywhich seems to be of distinct interestwhen trying to understand the process of heart valve
calciﬁcation. OPN also correlates with AVC-severity but is mostly dependent on the age of the patients.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The balance between angiogenic and angiostatic processes, which is
controlled by numerous factors, is of particular importance for a healthy
vascular system. However, angiogenesis also plays an important role in
pathological angiogenesis and calciﬁcation of cardiac valves although it
is rarely subject of investigation [1]. Calciﬁcation of aortic valves is the
most frequent valvular disease with a prevalence of about 3–9% [2].
Furthermore, it was shown that stenotic aortic valves contain 3 types
of neovessels: small andmediummicrovessels and organized arterioles.
In stenotic valves, the distribution of neovessels is signiﬁcantly higher
and correlateswith valvular calciﬁcation grade andmast cells in the ste-
notic area were shown to be activated and to contain VEGF [3].
ES is a component of nearly all endothelial basement membranes in
the human body and turned out to be, in the long run, a strong angiostatic
factor by inhibiting proliferation [4] of endothelial cells and tube forma-
tion [5] whereby it might also have angiogenic effects [6] depending on
its concentration and on the type of cell it interactswith [7]. Its circulatingM. Sponder).
td. This is an open access article undamounts are inﬂuenced by several secondary circumstances such as the
presence of diabetes [8] or physical activity [9]. Chalajour et al. investigat-
ed the angiogenic response of valvular endothelial cells to aortic valve ste-
nosis in an ex vivo model of aortic leaﬂets and showed that sprouts from
stenotic valves exhibited endostatin [10]. However,whereas recombinant
murine endostatinwas shown to inhibitmicrovessel formation in rat aor-
tic rings in an ex vivo model, human endostatin did not [11].
Although OPN is not counted among “classic” angiogenesis-factors
such as ES, it was suggested as a kind of “survival factor” for different
types of cells (e.g. vascular smoothmuscle cells [12]) andhas angiogenic
potential due to activation of PI3K/AKT- and ERK pathways through
VEGF in endothelial cells [13]. OPN was shown to be absent in native
non-calciﬁed human aortic valves but present in minimally and highly
calciﬁed ones [14]. Similar results were obtained for rheumatic and
non-rheumatic mitral valves [15,16]. A further study revealed that
OPN is not only present in living aortic valve tissue but also in calciﬁed
areas of bioprosthetic heart valves [17]. It gets synthesized mainly by
macrophages (and to a small amount by endothelial and smoothmuscle
cells) [18] and is localized at the surface of calciﬁed deposits [19]. A
correlation of elevated plasma levels of OPN and AVC was also found
in healthy elderly subjects [20] and dephosphorylation of OPNer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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volved in the process of calciﬁcation in bones [22] but on the other
hand it was also shown to stimulate bone resorption [23]. Concerning
vascular calciﬁcation, Wada et al. showed in a cell culture system that
exogenous OPN potently inhibited calciﬁcation by inhibition of apatite
growth [24].
ES and OPN doubtlessly play important roles in CAD but at present
their role in AVC is not clear.
2. Material and methods
2.1. Population
In total 161 male (mean age: 61.09 ± 11.02 years) and 63 female
(mean age: 67.49 ± 7.87 years) patients, never-smoker or ex-smoker
for at least 7 years, with angiographically veriﬁed CAD of different
severity were recruited. The protocol was approved by the Ethical
Committee of the Medical University of Vienna and informed written
consent was obtained from patients.
2.2. Deﬁnition of CAD
All patients underwent a coronary angiography for diagnostic and/or
therapeutic reasons on grounds of their underlying disease. The coro-
nary artery system was divided into 17 segments and stenosis grade
for each segment was measured. A simple 3-point-grading system
(“Coronary Score” [25]) was developed considering both frequency
and severity of CAD. The patients received 0 points for non-stenosed
or only calciﬁed segments, 1 point for each stenosis from b30–b50%, 2
points for each stenosis from 50–b70% and 3 points for each stenosis
N70%.
2.3. Echocardiographic analysis
Echocardiographic data were obtained with the use of the commer-
cially available ultrasound systems (GE Medical Systems Vivid 7 Dimen-
sions, Horton, Norway). Transthoracic echocardiography was performed
by experienced echocardiographer without knowing levels of ES or OPN
and was therefore “blinded”. The severity of AVC was assessed by two-Fig. 1. Severitdimensional echocardiography in a parasternal short axis view. Patients
with bicuspid aortic valveswere excluded from the evaluation of AVC be-
cause bicuspid aortic valves are associated with valvular calciﬁca-
tions per se.
The degree of calciﬁcation of the aortic valve (Fig. 1) was scored as
follows: 1: no calciﬁcation; 2: mild calciﬁcation (small isolated spots);
and 3: moderate/severe calciﬁcation (multiple larger spots or extensive
thickening and calciﬁcation of all cusps).
2.4. Endostatin and osteopontin analysis
ES was analyzed in serum, OPN in plasma by Enzyme-linked
Immunosorbent Assay (ELISA) according to the instructions of the
manufacturer.
2.5. Statistical analysis
Statistical analysis was done with SPSS 20.0. Continuous and nor-
mally distributed data is described by means ± standard deviation
(SD) and group differences were tested by independent sample t-test.
Univariate analysis of variance (ANOVA) was used to test the inﬂuence
of AVC severity on ES and OPN. In a next step variables signiﬁcantly re-
lated to AVC were entered as covariates. Ordinal logistic regression was
used to model signiﬁcant outcome variables onto AVC.
All tests are performed two-sided and p-values ≤0.05 were consid-
ered signiﬁcant.
3. Results
Important anthropometric data, blood pressure and results from
ECG are shown in Table 1. Female patients were about 6.5 years older,
had a signiﬁcantly lower BMI (p = 0.017) and diastolic blood pressure
(p b 0.001) andwere less commonly ex-smokers (p=0.003) compared
to men. No further signiﬁcant sex-speciﬁc differences occurred. Atrial
ﬁbrillation was observed in 23 patients, consequently, the PQ-interval
refers to the remaining 221 patients.
The coronary score representing the severity of CADwas signiﬁcant-
ly higher in male compared to female patients (p = 0.017). The most
frequently affected coronary segments were the medial and proximaly of AVC.
Table 1
Patient description.
Female Male Total p-Value
Age (years) 67.49 ± 7.87 61.09 ± 11.02 62.89 ± 10.61 b0.001
BMI (kg/m2) 26.80 ± 5.40 28.71 ± 4.90 28.17 ± 5.11 0.017
SBP (mm Hg) 131.82 ± 17.04 129.84 ± 16.15 130.39 ± 16.39 0.431
DBP (mm Hg) 72.30 ± 8.77 77.68 ± 11.77 76.16 ± 11.25 b0.001
HR (bpm) 69.95 ± 13.05 70.78 ± 13.31 70.54 ± 13.21 0.676
PQ (ms) 156.14 ± 32.02 165.65 ± 30.17 162.91 ± 30.94 0.055
QTc (ms) 452.14 ± 42.68 443.87 ± 35.45 446.23 ± 37.77 0.176
QRS (ms) 99.40 ± 23.08 103.99 ± 24.73 102.68 ± 24.31 0.206
Coronary score (points) 6.08 ± 5.63 8.02 ± 5.37 7.47 ± 5.50 0.017
Ex-smokers (%/n) 47.6/30 68.9/111 62.9/141 0.003
Diabetes mellitus (%/n) 34.9/22 26.1/42 28.6/64 0.189
Hypertension (%/n) 95.2/60 91.9/148 92.9/208 0.388
Hyperlipidemia (%/n) 88.9/56 91.9/148 91.1/204 0.475
Patient description: anthropometric data, systolic and diastolic blood pressure (SBP, DBP), heart rate (HR), data from ECG and prevalence of ex-smoking, diabetes mellitus, hypertension
and hyperlipidemia. Data is given as mean ± SD or %/n.
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and 30.8%) the proximal andmedial LCX (29.5 and 21.0%) and the distal
LAD (19.6%). The other segments (left main, intermediate branch, 1st
and 2nd marginal and diagonal branches, posterolateral branch, distal
LCX and ramus interventricularis posterior) were less commonly
affected.
AVC was present in 26.3% (n = 59) of 224 CAD-patients. As can be
seen from Table 2 and Fig. 2 ES and OPN levels increased signiﬁcantly
with a grade of AVC (ES: F = 7.6; p b 0.001; OPN: F = 3.6; p b 0.03).
ES and OPN levels increased from 196.45 ± 74.12/122.03 ±
65.36 ng/ml in patients without AVC to 217.51 ± 49.69/140.01 ±
65.35 ng/ml in patients with mild AVC (p = 0.150/p = 0.358) and to
250.22 ± 111.48/152.16 ± 71.71 ng/ml in patients with moderate/
severe AVC (p = 0.004/p = 0.015).
When entering age, BMI and CAD-severity score as covariates in the
univariate ANOVA, ESwas still signiﬁcantly dependent on AVC-severity,
but not OPN. The ordinal logistic regression model for AVC severity was
signiﬁcant (χ2 = 39.8, p b 0.001) but a moderate predictor (R2 = 0.23).
Signiﬁcant predictors in themodel were age (p b 0.0001), CAD-severity
score (p b 0.01), and ES (p b 0.04) but neither OPN nor BMI,4. Discussion
It is well-known that AVC-severity is of high predictive value regard-
ing progression and outcome of aortic valve stenosis. The role of ES and
OPN in valve calciﬁcation, especially in patients with CAD, is nearly
unexplored. In the present study we measured circulating levels of ES
and OPN in 224 patients with angiographically veriﬁed and quantiﬁed
CAD whereby 26.3% suffered AVC to gain insight into the role of ES
and OPN in AVC.
OPN, a non-collagenous glycosylated 44 kDa-phosphoprotein and
component of the mineralized bone, was shown in former studies to
be present in both living aortic valve tissue and calciﬁed areas of
bioprosthetic heart valves [17] and in plasma of healthy subjects with
aortic valve calciﬁcation [20]. Concerning OPN, our results conﬁrm pre-
vious ﬁndings: compared to patients without AVC, patients with mild
calciﬁcation had about 14.7%, and patients with moderate/severeTable 2
ES and OPN in AVC.
ES OPN
No AVC (n = 165) 196.45 ± 74.12 122.03 ± 65.36
Mild AVC (n = 15) 217.51 ± 49.69 140.01 ± 65.35
Mod./sev. AVC (n = 44) 250.22 ± 111.48 152.16 ± 71.71
SerumES and plasmaOPN levels (ng/ml) in dependence of AVC. Data is given asmean±SD.calciﬁcation had about 24.7% higher OPN levels. A stepwise increase in
OPN was shown before for the aortic valve [21] but not in patients
with per se elevated calciﬁcation status such as CAD-patients. However,
as our data show, the grade of AVC is rather dependent on the age of the
patient than on the circulating OPN amount. Valve calciﬁcation is char-
acterized by Ca++-deposition and accumulation resulting from several
circumstances (e.g. aging and inﬂammation) [26]. Our results suggest
that bone matrix proteins such as OPN which regulate Ca++-
deposition in bone and coronary arteries [27] might also be involved
in calciﬁcation of aortic valves in patients suffering CAD. All of our pa-
tients suffered CAD and were homologous concerning e.g. cardiovascu-
lar risk factors and routine laboratory parameters but OPNwashigher in
patients with moderate and severe AVC compared to a large group of
patients without calciﬁcations suggesting a distinct involvement of
OPN in valve calciﬁcation, despite the presence of CAD. But due to re-
sults of a study by Wada et al. [24] who suggested OPN to be a potent
preventive factor of pervasive vascular calciﬁcation it seemsmore likely
that OPN does not promote but counteracts valve calciﬁcation and
therefore is elevated in course of a calciﬁcation processes.Fig. 2. ES and OPN in AVC.
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serum ES levels and AVC, however, its interpretation is much more dif-
ﬁcult. Our results showed a strong correlation of ES and the grade of AVC
independent from age, BMI and CAD-severity. Whereas literature de-
livers at least some data and hints for OPN in valve calciﬁcation, there
is practically nothing available concerning ES. Neovascularization has
already been suspected to play a role in aortic stenosis and AVC [28,
29]. Healthy human aortic valves are per se avascular structures, how-
ever, calciﬁed valveswere shown to containmicrovessels and arterioles.
Compared to patients without AVC patients with mild AVC had about
10.7% and with moderate or severe calciﬁcation 27.4% higher serum
ES levels. Formerly, valve calciﬁcation was supposed to be a passive
and degenerative process with deposition of Ca++ into valve leaﬂets
as central pathological process. Nowadays, it is assumed that active pro-
cesses, in particular inﬂammation, are causal for this group of disease
and the deposition of Ca++- is “only” the last step. A mixture of angio-
genic and growth factors, inﬂammatory mediators, enzymes of matrix
remodeling, mechanical stimuli and others contribute to the genesis of
valve calciﬁcation [28,30,31]. However, as the results of the present
study show, also the angiostatic factor ES seems to be involved in this
process and that is anything but surprising considering that heart
valve calciﬁcation proceeds very similar to the pathogenesis of athero-
sclerosis or even the physiological process of bone calciﬁcation [32].
Syvaranta et al. [3] raised the possibility that mast cells could be patho-
genic players in valve neovascularization: they suspected mast cell-
derived tryptase to accelerate valvular neovascularization by degrading
ES. Several interactions are thinkable and might explain an ES increase
in AVC e.g. to counteract the VEGF-induced neovascularization which
is present in aortic stenosis or to counteract inﬂammatory activity
which has also been shown during the process of aortic AVC [26] but
due to the lack of data frommolecular research and considering the in-
volvement of ES in numerous mechanisms and pathways this remains
guesswork.5. Conclusion
We found a stepwise increase of circulating ES levels in AVCdepend-
ing on the grade of calciﬁcation and independent from age, BMI and
CAD-severity in a large study group of patients with angiographically
veriﬁed CAD suggesting a distinct role and maybe therapeutic possibil-
ity of ES in the process of valve calciﬁcation. To understand the role of ES
and neoangiogenesis in AVC further studies investigating the molecular
mechanisms are needed. OPN levels also correlated with AVC-severity
but were strongly inﬂuenced by the age of the patients.6. Limitations
Although in total a large number of 224 patients suffering CADwere
recruited the number of female patients was low (n = 63). A point of
criticism might be that angiogenic and angiostatic factors are per se
strongly inﬂuenced by the presence of CAD. However, for that reason
we had a broadnumber of CAD-patientswithout AVC delivering reliable
baseline levels and considered this aspect in the statistical analysis.Funding sources
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